Literature DB >> 25697548

The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose.

S M Salheen1, U Panchapakesan2, C A Pollock2, O L Woodman3.   

Abstract

The aim of the study was to investigate the effects of the DPP-4 inhibitors and GLP-1R agonist, exendin-4 on the mechanism(s) of endothelium-dependent relaxation in rat mesenteric arteries exposed to high glucose concentration (40 mM). Organ bath techniques were employed to investigate vascular endothelial function in rat mesenteric arteries in the presence of normal (11 mM) or high (40 mM) glucose concentrations. Pharmacological tools (1μM TRAM-34, 1μM apamin, 100 nM Ibtx, 100 μM l-NNA, 10 μM ODQ) were used to distinguish between NO and EDHF-mediated relaxation. Superoxide anion levels were assessed by L-012 and lucigenin enhanced-chemiluminescence techniques. Incubation of mesenteric rings with high glucose for 2 h caused a significant increase in superoxide anion generation and a significant impairment of endothelium-dependent relaxation. Exendin-4 and DPP-4 inhibitor linagliptin, but not sitagliptin or vildagliptin, significantly reduced vascular superoxide and improved endothelium-dependent relaxation in the presence of high glucose. The beneficial actions of exendin-4, but not linagliptin, were attenuated by the GLP-1R antagonist exendin fragment (9-39). Further experiments demonstrated that the presence of high glucose impaired the contribution of both nitric oxide and endothelium-dependent hyperpolarisation to relaxation and that linagliptin improved both mechanisms involved in endothelium-dependent relaxation. These findings demonstrate that high glucose impaired endothelium-dependent relaxation can be improved by exendin-4 and linagliptin, likely due to their antioxidant activity and independently of any glucose lowering effect.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dipeptidylpeptidase-4 inhibitors; Endothelium-dependent relaxation; Exendin-4; High glucose; Superoxide anion

Mesh:

Substances:

Year:  2015        PMID: 25697548     DOI: 10.1016/j.phrs.2015.02.003

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  16 in total

1.  Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells.

Authors:  Mohamed I Saad; Taha M Abdelkhalek; Moustafa M Saleh; Maher A Kamel; Mina Youssef; Shady H Tawfik; Helena Dominguez
Journal:  Endocrine       Date:  2015-08-14       Impact factor: 3.633

2.  Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.

Authors:  Michael E Widlansky; Venkata K Puppala; Tisha M Suboc; Mobin Malik; Amberly Branum; Kara Signorelli; Jingli Wang; Rong Ying; Michael J Tanner; Sudhi Tyagi
Journal:  Vasc Med       Date:  2017-02-01       Impact factor: 3.239

3.  Different mechanisms involved in liraglutide and glucagon-like peptide-1 vasodilatation in rat mesenteric small arteries.

Authors:  Maj Bangshaab; Alejandro Gutierrez; Khiem Dinh Huynh; Jakob Schöllhammer Knudsen; Daniel Dias Rufino Arcanjo; Asbjørn G Petersen; Jørgen Rungby; Michael Gejl; Ulf Simonsen
Journal:  Br J Pharmacol       Date:  2018-12-09       Impact factor: 8.739

4.  Exendin-4 protects HUVECs from tunicamycin-induced apoptosis via inhibiting the IRE1a/JNK/caspase-3 pathway.

Authors:  Li Wu; XiaoYing Liu; LinXi Wang; YanPing Wang; LiJing Wang; BinBin Guan; Zhou Chen; LiBin Liu
Journal:  Endocrine       Date:  2016-12-03       Impact factor: 3.633

5.  Diabetes-mediated middle cerebral artery remodeling is restored by linagliptin: Interaction with the vascular smooth muscle cell endothelin system.

Authors:  Abdul Yasir; Trevor Hardigan; Adviye Ergul
Journal:  Life Sci       Date:  2016-03-02       Impact factor: 5.037

6.  Possible vasculoprotective role of linagliptin against sodium arsenite-induced vascular endothelial dysfunction.

Authors:  Uma Jyoti; Sunil Kumar Kansal; Puneet Kumar; Sandeep Goyal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-02       Impact factor: 3.000

7.  THE IN VITRO CYTOTOXICITY, GENOTOXICITY AND OXIDATIVE DAMAGE POTENTIAL OF THE ORAL DIPEPTIDYL PEPTIDASE-4 INHIBITOR, LINAGLIPTIN, ON CULTURED HUMAN MONONUCLEAR BLOOD CELLS.

Authors:  K Çadirci; H Türkez; Ö Özdemir
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jan-Mar       Impact factor: 0.877

Review 8.  The Role of Dipeptidyl Peptidase - 4 Inhibitors in Diabetic Kidney Disease.

Authors:  Usha Panchapakesan; Carol Pollock
Journal:  Front Immunol       Date:  2015-08-28       Impact factor: 7.561

9.  DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome.

Authors:  Yochai Birnbaum; Dat Tran; Mandeep Bajaj; Yumei Ye
Journal:  Basic Res Cardiol       Date:  2019-08-06       Impact factor: 17.165

10.  The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose.

Authors:  Salheen M Salheen; Usha Panchapakesan; Carol A Pollock; Owen L Woodman
Journal:  PLoS One       Date:  2015-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.